Identification, treatment and management of cardiovascular risks in patients with acromegaly

References

• Melmed S. Medical progress: acromegaly. N. Engl. J. Med.355, 2558–2573 (2006).
   PubMed Web of Science ®Google Scholar
• Alexander L, Appleton D, Hall R, Ros WM, Wilkinson R. Epidemiology of acromegaly in the Newcastle region. Clin. Endocrinol. (Oxf.)12, 71–79 (1980).
   PubMed Web of Science ®Google Scholar
• Nabarro JDN. Acromegaly. Clin. Endocrinol. (Oxf.)26, 481–512 (1987).
   PubMed Web of Science ®Google Scholar
• Bengtosson BA, Eden S, Ernest I, Oden A, Sjogren B. Epidemiology and long term survival in acromegaly: a study of 166 cases diagnosed between 1955 and 1984. Acta Med. Scand.223, 327–335 (1988).
   PubMedGoogle Scholar
• Lamberts SWJ, van der Lely AJ, de Herder WW. Clinical and medical diagnosis of acromegaly. Metabolism44(1), 15–17 (1995).
   PubMedGoogle Scholar
• Wright AD, Hill DM, Lowy C, Fraser TR. Mortality in acromegaly. Q. J. Med.34, 1–16 (1970).
   Google Scholar
• Ritchie CM, Atkinson AB, Kennedy AL et al. Ascertainment and natural history of treated acromegaly in Northern Island. Ulster Med. J.5, 55–62 (1990).
   Google Scholar
• Bates AS, Van’t Hoff W, Kones JM, Clayton RN. An audit of outcome of treatment in acromegaly. Q. J. Med.86, 293–299 (1993).
   PubMedGoogle Scholar
• Extabe J, Gaztambide S, Latorre P, Vazquez JA. Acromegaly: an epidemiological study. J. Endocrinol. Invest.16, 181–187 (1993).
   PubMedGoogle Scholar
• Rajasoorya C, Holdaway IM, Wringhtson P, Scott DJ, Ibbertson HK. Determinants of clinical outcome and survival in acromegaly. Clin. Endocrinol. (Oxf.)41, 95–102 (1994).
   PubMed Web of Science ®Google Scholar
• Orme SM, McNally RJQ, Catwright RA, Belchetz PE. Mortality and cancer incidence in acromegaly: a retrospective cohort study. J. Clin. Endocrinol. Metab.83, 2730–2734 (1998).
   PubMed Web of Science ®Google Scholar
• Shimatsu A, Yokogoshi Y, Saito S, Shimizu N, Irie M. Long-term survival and cardiovascular complications in patients with acromegaly and pituitary gigantism. J. Endocrinol. Invest.21, 55–57 (1998).
   Google Scholar
• Abosh A, Tyrell JB, Lamborn KR, Hannegan LT, Applebury CB, Wilson CB. Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: initial ourcome and long-term results. J. Clin. Endocrinol. Metab.83, 3411–3418 (1998).
   PubMedGoogle Scholar
• Swearingen B, Barker FG, Katznelson L et al. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J. Clin. Endocrinol. Metab.83, 3419–3426 (1998).
   PubMed Web of Science ®Google Scholar
• Beauregard C, Troung U, Hardy J, Serri O. Long-term outcome and mortality transsphenoidal adenomectomy for acromegaly. Clin. Endocrinol. (Oxf.)58, 86–91 (2003).
   PubMed Web of Science ®Google Scholar
• Ayuk J, Clayton RN, Holder G, Sheppard MC, Stewart PM, Bates AS. Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. J. Clin. Endocrinol. Metab.89, 1613–1617 (2004).
   PubMed Web of Science ®Google Scholar
• Holdaway IM, Rajasoorya RC, Gamble GD. Factors influencing mortality in acromegaly. J. Clin. Endocrinol. Metab.89(2), 667–674 (2003).
   Google Scholar
• Kauppinen-Makelin R, Sane T, Reunanen A et al. A nationwide survey of mortality in acromegaly. J. Clin. Endocrinol. Metab.90, 4081–4086 (2005).
   PubMed Web of Science ®Google Scholar
• Colao AM, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr. Rev.25, 102–152 (2004).
   PubMed Web of Science ®Google Scholar
• Courville C, Mason WR. The heart in acromegaly. Arch. Intern. Med.61, 704–713 (1938).
   Google Scholar
• Clayton RN. New developments in the management of acromegaly. Should we achieve an absolute biochemical cure? J. Endocrinol.155(1), 23–29 (1997).
   Google Scholar
• Dekkers OM, Biemarsz NR, Pereira M, Romijn JA, Vandenbroucke JP. Mortality in acromegaly: a metaanalysis. J. Clin. Endocrinol. Metab.93, 61–67 (2008).
   PubMed Web of Science ®Google Scholar
• Melmed S. Acromegaly and cancer: not a probem. J. Endocrinol. Metab.86, 2929–2934 (2001).
   PubMed Web of Science ®Google Scholar
• Lu C, Schwartzbauer G, Sperling MA et al. Demonstration of direct effect of growth hormone on neonatal cardiomyocytes. J. Biol. Chem.276, 22892–22900 (2001).
   PubMedGoogle Scholar
• Otsuki M, Kasayama S, Yamamoto H et al. Characterization of premature atherosclerosis of carotid arteries in acromegalic patients. Clin. Endocrinol. (Oxf.).54, 791–796 (2001).
   PubMedGoogle Scholar
• Hejtmancik MR, Bradfield JY, Herrmann GR. Acromegaly and heart: a clinical and pathologic study. Ann. Intern. Med.34, 1445–1456 (1950).
   Google Scholar
• Goldberg MB, Lisser H. Acromegaly: a consideration of its course and treatment. Report of four cases with autopsies. J. Clin. Endocrinol.2, 477–501 (1942).
   Google Scholar
• Colao A, Baldelli R, Marzullo P et al. Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy. J. Clin. Endocrinol. Metab.85(1), 193–199 (2000).
   PubMed Web of Science ®Google Scholar
• Huchard H. Anatomie pathologique, lesions et trouble cardiovasculaires de l’acromegalie. J. Practiciens9, 249–250 (1895).
   Google Scholar
• Lie JT, Grossman SJ. Pathology of the heart in acromegaly: anatomic findings in 27 autopsied patients. Am. Heart J.100, 41–52 (1980).
   PubMed Web of Science ®Google Scholar
• Sacca’ L, Cittadini A, Fazio S. Growth hormone and the heart. Endocr. Rev.24, 272–277 (2003).
   PubMedGoogle Scholar
• Clayton RN. Cardiovascular function in acromegaly. Endocr. Rev.24, 272–277 (2003).
   PubMed Web of Science ®Google Scholar
• Ciulla M, Arosio M, Barelli MV et al. Blood-pressure independent cardiac hypertrophy in acromegalic patients. J. Hypertens.17, 1965–1969 (1999).
   PubMedGoogle Scholar
• Frustaci A, Chimenti C, Setoguchi M et al. Cell death in acromegalic cardiomyopathy. Circulation99(11), 1426–34 (1999).
   PubMed Web of Science ®Google Scholar
• Cittadini A, Stromer H, Katz SE et al. Differential cardiac effects of growth hormone and IGF1 in the rat. A combined in vivo and in vitro evaluation. Circulation93, 800–809 (1996).
   PubMed Web of Science ®Google Scholar
• Imanishi R, Ashizawa N, Ohtsuru A et al. GH suppresses TGF-b-mediated fibrosis and retains cardiac diastolic function. Mol. Cell. Endocrinol.218, 137–146 (2004).
   PubMedGoogle Scholar
• Bihan H, Espinosa C, Valdes-Socin H et al. Long-term outcome of patients with acromegaly and congestive heart failure. J. Clin. Endocrinol. Metab.89, 5308–5313 (2004).
   PubMed Web of Science ®Google Scholar
• Morvan D, Komajada M, Grimaldi A, Turpin G, Grosgogeat Y. Cardiac function and hypertrophy and function in asymptomatic acromegaly. Eur. Heart J.12, 666–672 (1991).
   PubMedGoogle Scholar
• Colao AM, Marzullo P, Di Somma C, Lombardi G. Growth hormone and the heart. Clin. Endocrinol. (Oxf.)54, 137–154 (2001).
   PubMed Web of Science ®Google Scholar
• Hayward RP, Emanuel RW, Nabarro JDN. Acromegalic heart disease: influence and treatment of acromegaly on the heart Q. J. Med.62, 41–58 (1987).
   PubMedGoogle Scholar
• Colao A, Cuocolo A, Marzullo P et al. Impact of patient’s age and disease duration on cardiac performance in acromegaly: a radionuclide angiography study. J. Clin. Endocrinol. Metab.84, 1518–1523 (1999).
   PubMedGoogle Scholar
• Vianna CB, Vieiria MLC, Mady C et al. Treatment of acromegaly improves myocardial abnormalities. Am. Heart J.143, 873–876 (2002).
   PubMed Web of Science ®Google Scholar
• Pivonello R, Galderisi M, Auriemma RS et al. Treatment with GH receptor antagonist in acromegaly: effect on cardiac structure and performance. J. Clin. Endocrinol. Metab.92, 476–482 (2007).
   PubMed Web of Science ®Google Scholar
• Herrmann BL, Brunch C, Saller B et al. Acromegaly: evidence for a direct relation between disease activity and cardiac dysfunction in patients without ventricular hypertrophy. Clin. Endocrinol. (Oxf.)56, 595–602 (2002).
   PubMedGoogle Scholar
• Mercuro G, Zoncu S, Colonna P et al. Cardiac dysfunction in acromegaly: evidence by pulsed wave tissue doppler imaging. Eur. J. Endocrinol.143, 363–369 (2000).
   PubMedGoogle Scholar
• Bogazzi F, Di Bello V, Palagi C et al. Improvement of intrinsic myocardial contractility and cardiac fibrosis degree in acromegalic patients treated with somatostatin analogues: a prospective study. Clin. Endocrinol. (Oxf.)62, 590–596 (2005).
   PubMed Web of Science ®Google Scholar
• Di Bello V, Bogazzi F, Di Cori A et al. Myocardial systolic strani abnormalities in patients with acromegaly: a prospective color Doppler imaging study. J. Endocrinol. Invest.29(6), 544–550 (2006).
   PubMedGoogle Scholar
• Bogazzi F, Lombardi M, Strata E et al. High prevalence of cardiac hypertophy without detectable signs of fibrosis in patients with untreated active acromegaly: an in vivo study using magnetic resonance imaging. Clin. Endocrinol.68, 361–368 (2008).
   PubMed Web of Science ®Google Scholar
• Ciulla MM, Eoaminonda P, Paliotti R et al. Evaluation of acrdiac structure by echoreflectivity analysis in acromegaly: efffects of treatment. Eur. J. Endocrinol.151, 179–186 (2004).
   PubMed Web of Science ®Google Scholar
• De Marinis L, Bianchi A, Mazziotti G et al. The long-term cardiovascular outcome of different GH-lowering treatments in acromegaly. Pituitary11, 13–20 (2008).
   PubMed Web of Science ®Google Scholar
• Colao A, Pivonello R, Galderisi M et al. Impact of treating acromegaly first with surgery or somatostatin analogs on cardiomyopathy. J. Clin. Endocrinol. Metab.93, 2639–2646 (2008).
   PubMed Web of Science ®Google Scholar
• Schocken DD, Benjamin EJ, Fonarow GC et al. Prevention of heart failure: a scientific statement from the American Heart Association Councils on Epidemiology and Prevention, Clinical Cardiology, Cardiovascular Nursing, and High Blood Pressure Research; Quality of Care and Outcomes Research Interdisciplinary Working Group; and Functional Genomics and Translational Biology Interdisciplinary Working Group. Circulation117, 2544–2565 (2008).
   PubMed Web of Science ®Google Scholar
• Maison P, Tropeano AI, Macquin-Mavier I, Giustina A, Chanson P. Impact of somatostatin analogs on the heart in acromegaly: a metaanalysis. J. Clin. Endocrinol. Metab.92, 1743–1747 (2007).
   PubMed Web of Science ®Google Scholar
• Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N. Engl. J. Med.322, 1561–1566 (1990).
   PubMed Web of Science ®Google Scholar
• Colao A, Marzullo P, Lombardi G; Italian Multicenter Study Group on Lanreotide. Effects of a six-month treatment with lanreotide on cardiovascular risk factors and arterial intima-media thickness in patients with acromegaly. Eur. J. Endocrinol.146, 303–330 (2002).
   PubMed Web of Science ®Google Scholar
• Bay HB, Pollman M, Inishi Y, Gibbons GH. Regulation of vascular smooth muscle cell apoptosis: modulation of Bad by phosphatidylinositol 3-kinase dependent pathway. Circ. Res.85, 229–237 (1999).
   PubMedGoogle Scholar
• Meng D, Lv DD, Fang J. Insulin-like growth factors I induces reactive oxygen species production and cell migration through Nox4 and Rac1 in vascular smooth muscle cells. Cardiovasc. Res. (2008) (Epub ahead of print) [DOI: 10.1093/cvr/cvn173].
   Google Scholar
• Michell BJ, Griffiths JE, Mitchelhill KI et al. The Akt kinase signals directly to endothelial nitric oxide synthase. Curr. Biol.9, 845–848 (1999).
   PubMed Web of Science ®Google Scholar
• Patel VA, Zhang QJ, Siddle K et al. Defect in insuline like growth factor-1 survival mechanism in atherosclerotic plaque-derived vascular smooth muscle cells mediated by reduced surface binding and signaling. Circ. Res.88, 895–902 (2001).
   PubMedGoogle Scholar
• Sandberg EM, Sayeski PP. Jak2 tyrosine kinase mediates oxidative stess-induced apoptosis in vascular smooth muscle cell. J. Biol. Chem.279, 34547–34552 (2004).
   PubMed Web of Science ®Google Scholar
• Rosen T, Eden S, Larson G, Wilhelmsen L, Bengtsson BA. Cardiovascular risk factors in adult patients with growth hormone deficiency. Acta Endocrinol.129, 195–200 (1993).
   PubMedGoogle Scholar
• Lanes R, Soros A, Flores K, Gunczler P, Carillo E, Bandel J. Endothelial function, carotid artery intima-media thickness, epicardial adipose tissue, and left ventricular mass and function in growth hormone-deficient adolescent: apparent effects of growth hormone treatment on these parameters. J. Clin. Endocrinol. Metab.90, 3978–3982 (2005).
   PubMed Web of Science ®Google Scholar
• Cannavò S, Almoto B, Cavalli G et al. Acromegaly and coronaric disease: an integrated evaluation of conventional coronary risk factors and coronary calcifications detected by computed tomography. J. Clin. Endocrinol. Metab.91, 3766–3772 (2006).
   PubMedGoogle Scholar
• Bogazzi F, Battolla L, Spinelli C et al. Risk factors for development of coronary heart disease in patients with acromegaly: a five-year prospective study. J. Clin. Endocrinol. Metab.92, 4271–4277 (2007).
   PubMed Web of Science ®Google Scholar
• Adreassen M, Vestergaard H, Kristensen L. Concentretions of the acute phase reactants high sensitive C-reative protein and YKL-40 and interleukin-6 before and after treatment in patients with acromegaly and growth hormone deficiency. Clin. Endocrinol. (Oxf.)67, 909–916 (2007).
   PubMedGoogle Scholar
• Schiavon F, Maffei P, Martini C et al. Morphologic study of microcirculation in acromegaly by capillaroscopy. J. Clin. Endocrinol. Metab.84, 3151–3155 (1999).
   PubMed Web of Science ®Google Scholar
• Dullart RP, Meijer S, Marbach P, Sluiter WJ. Effect of somatostatin analogue Octreotide on renal haemodynamics and albuminuria in acromegalic patients. Eur. J. Clin. Invest.22, 494–502 (1992).
   PubMedGoogle Scholar
• Avangina P, Martini M, Terzolo M et al. Assesment of functional liver mass and plasma flow in acromegaly before and after long term treatment with octerotide. Metabolism45, 109–113 (1996).
   Google Scholar
• Otsuki M, Kasamaya S, Hiroyasu Y et al. Characterization of premature atherosclerosis of carotid arteries in acromegalic patients. Clin. Endocrinol. (Oxf.)54, 791–796 (2001).
   PubMedGoogle Scholar
• Brevetti G, Marzullo P, Silevstro A et al. Early vascular alterations in acromegaly. J. Clin. Endocrinol. Metab.87, 3174–3179 (2002).
   PubMed Web of Science ®Google Scholar
• Kahaly G, Olhausen KV, Mohr-Kahaly S et al. Arrhytmia profile in acromegaly. Eur. Heart J.13, 51–56 (1992).
   PubMed Web of Science ®Google Scholar
• Rodrigues EA, Caruana MP, Lahiri A, Nabarro JD, Jacobs HS, Raftery EB. Subclinical cardiac dysfunction in acromegaly: evidence for a specific disease of heart muscle. Br. Heart J.62, 185–194 (1989).
   PubMedGoogle Scholar
• Mohamed AL, Yusoff K, Muttalif AR, Khalid BA. Markers of ventricular tachyarrythmias in patients with acromegaly. Med. J. Malaysia54, 338–345 (1999).
   PubMedGoogle Scholar
• Lombardi G, Colao A, Marzullo P, Biondi B, Palmieri E, Fazio S. Improvement of left ventricular hypertophy and arrhytmias after lanreotide induced GH and IGF1 decrease in acromegaly. A prospective multi-center study. J. Endocrinol. Invest.25, 971–976 (2002).
   PubMed Web of Science ®Google Scholar
• Fatti LM, Scacchi M, Lavezzi E et al. Effect of treatment with somatostatin analogues on QT interval duration in acromegalic patients. Clin. Endocrinol. (Oxf.)65, 636–30 (2006).
   Google Scholar
• Colao A, Spinelli L, Marzullo P et al. High prevalence of cardiac valve disease in acromegaly: an observational analytical prospective case–control study. J. Clin. Endocrinol. Metab.88(1), 3196–3201 (2003).
   PubMed Web of Science ®Google Scholar
• Pereira AM, van Thiel SW, Lindner JR et al. Increased prevalence of regurgitation valvular heart disease in acromegaly. J. Clin. Endocrinol. Metab.89, 71–75 (2004).
   PubMed Web of Science ®Google Scholar
• van der Klaauw AA, Bax JJ, Roelfsema F, Bleeker GB, Holman ER, Corssmit EP. Uncontrolled acromegaly is associated with progressive mitral valvular regurgitation. Growth Horm. IGF Res.16, 101–107 (2006).
   PubMed Web of Science ®Google Scholar
• Shade R, Andersohn F, Suissa S, Haverkamp W, Garbe E. Dopamine agonist and the risk of cardiac-valve regurgitation. N. Engl. J. Med.356, 29–39 (2007).
   PubMedGoogle Scholar
• Bogazzi F, Buralli S, Manetti L et al. Treatment with low doses of cabergoline is not associated with increased prevalence of cardiac valve regurgitation in patients with hyperprolactinemia. Int. J. Clin. Pract. DOI: 10.1007/s11102-008-0134-2 (2008).
   Google Scholar
• Vallette S, Serri K, Rivera J et al. Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas. Pituitary DOI: 10.1007/s11102-008-0134-2 (2008) (Epub ahead of print).
   Google Scholar
• Kars M, Delgado V, Holman ER et al. Aortic valve calcification and mild tricuspidal regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma. J. Clin. Endocrinol. Metab. DOI: 10.1210/jc.2007-2658 (2008) (Epub ahead of print).
   PubMedGoogle Scholar
• Colao A, Marek J, Goth MI et al. No greater incidence or worsening of cardiac valve regurgitation with somatostatin analog treatment of acromegaly. J. Clin. Endocrinol. Metab.93, 2243–2248 (2008).
   PubMed Web of Science ®Google Scholar
• Mulatero P, Veglio F, Maffei P et al.CYP11B2 _344T/C gene polymorphism and blood pressure in patients with acromegaly. J. Clin. Endocrinol. Metab.91, 5008–5050 (2006).
   PubMedGoogle Scholar
• Gordon DA, Hill FM, Ezrin C. Acromegaly: a review of 100 cases. Can. Med. Assoc. J.87, 1106–1109 (1962).
   PubMedGoogle Scholar
• Ezzat S, Forster MJ, Berchtold P, Redelmeier DA, Boerlin V, Harris AG. Acromegaly. Clinical and biochemical features in 500 patients. Medicine73, 233–240 (1994).
   PubMed Web of Science ®Google Scholar
• Bondanelli M, Ambrosio MR, Degli Uberti EC. Pathogenesis and prevalence of hypertension in acromegaly. Pituitary4, 239–249 (2001).
   PubMedGoogle Scholar
• Pietrobelli DJ, Akopian M, Olivieri AO et al. Altered circadian blood pressure profile in patients with active acromegaly. Relationship with left ventricular mass and hormonal values. J. Hum. Hypertens.15, 601–605 (2001).
   PubMed Web of Science ®Google Scholar
• Vitale G, Pivonello R, Auriemma RS et al. Hypertension in acromegaly and in the normal population: prevalence and determinants. Clin. Endocrinol. (Oxf.)63, 470–476 (2005).
   PubMed Web of Science ®Google Scholar
• Ohtsuka H, Komiya I, Aizawa T, Yamada T. Hypertension in acromegaly: hereditary hypertensive factor produces hypertension by enhancing IGF-I production. Endocr. J.42, 781–787 (1995).
   PubMed Web of Science ®Google Scholar
• Terzolo M, Matrella C, Boccuzzi A et al. Twenty four hour profile of blood pressure in patients with acromegaly. Correlation with demographic, clinical and hormonal features. J. Endocrinol. Invest.22, 48–54 (1999).
   PubMedGoogle Scholar
• Fallo F, Barzon L. Boscaro M, Consiglia E, Sonino N. Effect of octreotide on 24h blood pressure profile in acromegaly. Am. J. Hypertens.11(5), 591–596 (1998).
   PubMedGoogle Scholar
• Deray G, Chanson P, Maistre G et al. Atrial natriuretic factor in patients with acromegaly. Eur. J. Clin. Pharmacol.38, 409–413 (1990).
   PubMedGoogle Scholar
• Strauch G, Vallotton MB, Touitou Y, Bricaire H. The renin–angiotensin–aldosterone system in normotensive and hypertensive patients with acromegaly. N. Engl. J. Med.287, 795–799 (1972).
   PubMed Web of Science ®Google Scholar
• Ikkos D, Luft R, Sjogren B. Body water and sodium in patients with acromegaly. J. Clin. Invest.33, 989–994 (1954).
   PubMed Web of Science ®Google Scholar
• Snow MH, Piercy DA, Robson V, Wilkinson R. An investigation into the pathogenesis of hypertension in acromegaly. Clin. Sci. Mol. Med.53, 87–91 (1977).
   PubMedGoogle Scholar
• Davies DL, Beastall GH, Connell JM, Fraser R, McCruden D, Teasdale GM. Body composition, blood pressure and the renin–angiotensin system in acromegaly before and after treatment. J. Hypertens.3, S413–S415 (1985).
   Google Scholar
• Ritchie CM, Sheridan B, Fraser R et al. Studies on the pathogenesis of hypertension in Cushing’s disease and acromegaly. Q. J. Med.76, 855–867 (1990).
   PubMedGoogle Scholar
• McKnight JA, McCance DR, Hadden DR et al. Basal and saline-stimulated levels of plasma atrial natriuretic factor in acromegaly. Clin. Endocrinol. (Oxf.)31, 431–438 (1989).
   PubMedGoogle Scholar
• Chanson P, Mengnien JL, del Pino M et al. Decreased regional blood flow in patients with acromegaly. Clin. Endocrinol. (Oxf.)49, 725–731 (1998).
   PubMed Web of Science ®Google Scholar
• Colao A, Martino E, Cappabianca P, Cozzi R, Scanarini M, Ghigo E; A.L.I.C.E. Study Group. First-line therapy of acromegaly: a statement of the A.L.I.C.E. (Acromegaly primary medical treatment Learning and Improvement with Continuous Medical Education) Study Group. J. Endocrinol. Invest.29, 1017–1020 (2006).
   PubMed Web of Science ®Google Scholar
• Colao A. The GH/IGF axis and the cardiovascular system: clinical implications. Clin. Endocrinol. DOI: 10.1111/j.1365-2265.2008.03292.x (2008) (Epub ahead of print).
   Google Scholar
• Colao A, Di Somma C, Savanelli MC, Di Leo M, Lomabrdi G. Beginning to end: cardiovascular implications of growth hormone (GH) deficiency and GH therapy. Growth Horm. IGF Res.16(Suppl. A), S41–S48 (2006).
   PubMed Web of Science ®Google Scholar
• Follin C, Thilén U, Arhèn B, Erfurth EM. Improvement in cardiac systolic function and reduced of metabolic syndrome after two years of growth hormone (GH) treatment in GH-deficient adult survivors of childohood-onset acute lympoblastic leukaemia. J. Clin. Endocrinol. Metab.91, 1872–1875 (2006).
   PubMedGoogle Scholar